Cellares valuation, funding and investors
Cellares works in cell therapy manufacturing, based in South San Francisco, United States. Founded in 2019, it has about 327 employees.
- Last round
- Series D · $257M · Jan 2026
- Valuation at last round
- $3.20B · implied
- Headcount
- 327 · up
- Grade
- B
- Founded
- 2019
Cellares valuation today
VCMC values Cellares at $4.0B today, with a range of $2.3B to $6.1B and a grade of B. The valuation starts from its last funding round, a Series D round in Jan 2026.
Valuation by date (98 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $14.7M | $5.33M – $40.2M | $16.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $14.8M | $5.38M – $40.6M | $16.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $14.9M | $5.43M – $41.0M | $16.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $15.1M | $5.48M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $15.2M | $5.53M – $41.7M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $16.2M | $5.89M – $44.4M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.3M | $5.94M – $44.8M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.5M | $6.00M – $45.2M | $18.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.6M | $6.05M – $45.6M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $16.8M | $6.11M – $46.1M | $18.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $16.9M | $6.16M – $46.5M | $18.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $16.9M | $6.15M – $46.4M | $18.8M (+11%) | before first round | 15 | unknown | D | 0% |
| 1 Feb 2021 | $17.1M | $6.21M – $46.8M | $19.0M (+11%) | before first round | 15 | unknown | D | 0% |
| 1 Mar 2021 | $17.2M | $6.26M – $47.2M | $19.1M (+11%) | before first round | 15 | unknown | D | 0% |
| 1 Apr 2021 | $17.3M | $6.32M – $47.7M | $19.2M (+11%) | before first round | 15 | flat | D | 0% |
| 1 May 2021 | $28.2M | $12.1M – $56.1M | $31.2M (+11%) | before first round | 39 | growing | C | 0% |
| 6 May 2021 | $586M | $385M – $1.3B | $879M (+50%) | after a round | 39 | growing | C | 0% |
| 1 Jun 2021 | $604M | $385M – $1.3B | $879M (+46%) | after a round | 39 | growing | C | 0% |
| 1 Jul 2021 | $624M | $385M – $1.3B | $879M (+41%) | after a round | 39 | growing | C | 0% |
| 1 Aug 2021 | $646M | $385M – $1.3B | $879M (+36%) | after a round | 39 | growing | C | 0% |
| 1 Sep 2021 | $668M | $385M – $1.3B | $879M (+31%) | after a round | 39 | growing | C | 0% |
| 1 Oct 2021 | $691M | $385M – $1.3B | $879M (+27%) | after a round | 39 | growing | C | 0% |
| 1 Nov 2021 | $715M | $385M – $1.3B | $879M (+23%) | after a round | 39 | growing | C | 0% |
| 1 Dec 2021 | $739M | $385M – $1.3B | $879M (+19%) | after a round | 39 | growing | C | 0% |
| 1 Jan 2022 | $765M | $385M – $1.3B | $879M (+15%) | after a round | 39 | growing | C | 0% |
| 1 Feb 2022 | $792M | $385M – $1.3B | $879M (+11%) | after a round | 39 | growing | C | 0% |
| 1 Mar 2022 | $817M | $385M – $1.3B | $879M (+8%) | after a round | 39 | growing | C | 0% |
| 1 Apr 2022 | $846M | $385M – $1.3B | $879M (+4%) | after a round | 39 | growing | C | 0% |
| 1 May 2022 | $874M | $385M – $1.3B | $879M (0%) | after a round | 39 | growing | C | 0% |
| 1 Jun 2022 | $879M | $389M – $1.3B | $879M (0%) | after a round | 39 | growing | C | 0% |
| 1 Jul 2022 | $879M | $393M – $1.3B | $879M (0%) | after a round | 39 | growing | C | 0% |
| 1 Aug 2022 | $879M | $398M – $1.3B | $879M (0%) | after a round | 39 | growing | C | 0% |
| 1 Sep 2022 | $879M | $403M – $1.3B | $879M (0%) | after a round | 39 | growing | B | 0% |
| 1 Oct 2022 | $879M | $408M – $1.3B | $879M (0%) | after a round | 39 | growing | B | 0% |
| 1 Nov 2022 | $879M | $298M – $1.3B | $879M (0%) | after a round | 39 | unknown | C | 0% |
| 1 Dec 2022 | $879M | $285M – $1.3B | $879M (0%) | after a round | 39 | unknown | C | 0% |
| 1 Jan 2023 | $1.1B | $350M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 1 Feb 2023 | $1.1B | $334M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 1 Mar 2023 | $1.1B | $321M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 1 Apr 2023 | $1.1B | $308M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 1 May 2023 | $1.1B | $295M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 1 Jun 2023 | $1.1B | $259M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 1 Jul 2023 | $1.1B | $246M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 1 Aug 2023 | $1.1B | $234M – $1.7B | $1.1B (0%) | after a round | 120 | unknown | C | 0% |
| 24 Aug 2023 | $2.1B | $1.5B – $3.9B | $2.8B (+30%) | after a round | 120 | unknown | B | 0% |
| 1 Sep 2023 | $2.1B | $1.5B – $3.9B | $2.8B (+29%) | after a round | 120 | unknown | B | 0% |
| 1 Oct 2023 | $2.2B | $1.5B – $3.9B | $2.8B (+26%) | after a round | 160 | up | B | 0% |
| 1 Nov 2023 | $2.2B | $1.5B – $3.9B | $2.8B (+24%) | after a round | 160 | up | B | 0% |
| 1 Dec 2023 | $2.3B | $1.5B – $3.9B | $2.8B (+21%) | after a round | 160 | up | B | 0% |
| 1 Jan 2024 | $2.3B | $1.5B – $3.9B | $2.8B (+18%) | after a round | 160 | up | B | 0% |
| 1 Feb 2024 | $2.4B | $1.5B – $4.0B | $2.8B (+17%) | after a round | 170 | growing | B | 0% |
| 1 Mar 2024 | $2.5B | $1.5B – $4.0B | $2.8B (+15%) | after a round | 180 | growing | B | 0% |
| 1 Apr 2024 | $2.5B | $1.5B – $4.0B | $2.8B (+12%) | after a round | 180 | growing | B | 0% |
| 1 May 2024 | $2.6B | $1.5B – $4.0B | $2.8B (+9%) | after a round | 180 | growing | B | 0% |
| 1 Jun 2024 | $2.7B | $1.5B – $4.0B | $2.8B (+7%) | after a round | 180 | growing | B | 0% |
| 1 Jul 2024 | $2.7B | $1.5B – $4.0B | $2.8B (+4%) | after a round | 180 | growing | B | 0% |
| 1 Aug 2024 | $2.9B | $1.6B – $4.2B | $2.9B (+2%) | after a round | 210 | up | B | 0% |
| 1 Sep 2024 | $2.9B | $1.6B – $4.2B | $2.9B (0%) | after a round | 210 | up | B | 0% |
| 1 Oct 2024 | $2.9B | $1.6B – $4.2B | $2.9B (0%) | after a round | 210 | up | B | 0% |
| 1 Nov 2024 | $3.0B | $1.6B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Dec 2024 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Jan 2025 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Feb 2025 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Mar 2025 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Apr 2025 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 May 2025 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Jun 2025 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Jul 2025 | $3.0B | $1.7B – $4.3B | $3.0B (0%) | after a round | 230 | growing | B | 0% |
| 1 Aug 2025 | $3.1B | $1.8B – $4.5B | $3.1B (0%) | after a round | 284 | growing | B | 0% |
| 1 Sep 2025 | $3.1B | $1.7B – $4.5B | $3.1B (0%) | after a round | 284 | growing | B | 0% |
| 1 Oct 2025 | $3.1B | $1.3B – $4.4B | $3.1B (0%) | after a round | 278 | up | C | 0% |
| 1 Nov 2025 | $3.1B | $1.3B – $4.4B | $3.1B (0%) | after a round | 278 | up | C | 0% |
| 1 Dec 2025 | $3.1B | $1.3B – $4.4B | $3.1B (0%) | after a round | 278 | up | C | 0% |
| 1 Jan 2026 | $3.1B | $1.3B – $4.4B | $3.1B (0%) | after a round | 278 | up | C | 0% |
| 29 Jan 2026 | $3.2B | $2.3B – $5.9B | $4.2B (+30%) | after a round | 278 | up | B | 0% |
| 1 Feb 2026 | $3.2B | $2.3B – $5.9B | $4.2B (+30%) | after a round | 291 | growing | B | 0% |
| 1 Mar 2026 | $3.3B | $2.3B – $5.9B | $4.2B (+27%) | after a round | 291 | up | B | 0% |
| 1 Apr 2026 | $3.4B | $2.3B – $5.9B | $4.2B (+24%) | after a round | 291 | up | B | 0% |
| 1 May 2026 | $3.4B | $2.3B – $6.0B | $4.2B (+22%) | after a round | 303 | up | B | 0% |
| 1 Jun 2026 | $3.5B | $2.3B – $6.0B | $4.2B (+20%) | after a round | 303 | flat | B | 0% |
| 1 Jul 2026 | $3.6B | $2.3B – $6.0B | $4.2B (+17%) | after a round | 303 | flat | B | 0% |
| 1 Aug 2026 | $3.7B | $2.3B – $6.0B | $4.3B (+15%) | after a round | 323 | up | B | 0% |
| 1 Sep 2026 | $3.8B | $2.3B – $6.0B | $4.3B (+12%) | after a round | 323 | up | B | 0% |
| 1 Oct 2026 | $3.9B | $2.3B – $6.1B | $4.3B (+10%) | after a round | 327 | up | B | 0% |
| 24 Oct 2026 | $4.0B | $2.3B – $6.1B | $4.3B (+8%) | after a round | 327 | up | B | 0% |
Key facts about Cellares
- Founded
- 2019
- Headquarters
- South San Francisco, United States
- Employees
- about 327 +18% in a year
- Total raised
- $594M
- Funding rounds
- 3
- Last round
- Series D Jan 2026
Cellares was founded in 2019 by Alex Pesch, Fabian Gerlinghaus and Omar Kurdi.
Cellares funding history
Cellares has 3 funding rounds on record, from May 2021 to Jan 2026, $594M in total. None disclosed a valuation.
Series D 28 Jan 2026
Led by BlackRock, Eclipse; with T. Rowe Price Investment Management, Inc., Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, Willett Advisors.
Sources: cellares.com, cellgenetherapyreview.com, njbiz.com and 3 more
$257M
Series C 23 Aug 2023
Led by Koch Disruptive Technologies; with Bristol Myers Squibb, DFJ Growth, Willett Advisors, Eclipse, Decheng Capital, 8VC.
Sources: cellares.com, prnewswire.com, cooley.com and 3 more
$255M
Series B 5 May 2021
Led by Decheng Capital, Eclipse; with Skyviews Life Science, 8VC.
Sources: cellares.com, fiercepharma.com, biopharminternational.com
$82M
Cellares investors
16 investors have backed Cellares; Eclipse, Decheng Capital and BlackRock and 1 more led at least one round.
- Eclipse lead, 3 rounds
- Decheng Capital lead, 2 rounds
- BlackRock lead
- 8VC 2 rounds
- DFJ Growth 2 rounds
- Willett Advisors 2 rounds
- Baillie Gifford
- Bristol Myers Squibb
- DC Global Ventures
- Duquesne Family Office
- EDBI
- Gates Frontier
- Intuitive Ventures
- Skyviews Life Science
- T. Rowe Price Investment Management, Inc.
What Cellares does
Cellares works in pharmaceutical products, with 15 recorded offerings and customers in healthcare, pharmaceuticals and biotechnology.
Cellares Corporation is an American company engaged in integrated development and manufacturing of cell therapy products. The company provides services in preclinical and clinical research, technology development, manufacturing, and regulatory support for cell therapy applications. Cellares operates a global network of smart factories, including facilities in the United States, Europe, and Asia, and utilizes proprietary technologies for cell therapy manufacturing, automation, and quality control. The company collaborates with pharmaceutical and biotechnology partners and serves a global market.
Description from Veridion's company data.
Products and services
- Cell Therapy Manufacturing
- Preclinical and Clinical Services
- Cell Therapy Technology Development
- Regulatory Support Services
- Smart Factory Deployment and Operation
- Cell Shuttle Platform Integration
- Consumable Cartridge Integration
- Cell Q System Integration
- Automation Solutions Development
- Quality Control Solutions Implementation
- Global Cell Therapy Manufacturing Solutions
- Collaborative Drug Development Services
- Manufacturing Process Optimization Consulting
- Industry 4.0 Technology Implementation
- Smart Factory Expansion Services
Markets
- Healthcare
- Pharmaceuticals
- Biotechnology
Technology
- Cell Shuttle®
- Consumable Cartridge
- Cell Q®
- Industry 4.0 Technologies for Cell Therapy Manufacturing
Business model
- Business-to-Business
- Service Provider
- Manufacturing
- Enterprise
Industry codes (NAICS)
- 325414 Biological Product (except Diagnostic) Manufacturing 70% match
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 30% match
Questions about Cellares
What is Cellares worth?
Valuation $4.0B (range $2.3B to $6.1B), as of 24 Oct 2026.
Has Cellares raised money?
Cellares has 3 funding rounds on record, from May 2021 to Jan 2026, $594M in total. None disclosed a valuation.
Who has invested in Cellares?
Eclipse, Decheng Capital, BlackRock, Koch Disruptive Technologies, 8VC and DFJ Growth, and 10 more. Lead investors include Eclipse, Decheng Capital, BlackRock and Koch Disruptive Technologies.
How many people work at Cellares?
About 327, up 18% over the last year. Headcount grew from 15 in Jan 2021 to 327 in Sep 2026.
What does Cellares do?
Cellares works in pharmaceutical products, with 15 recorded offerings and customers in healthcare, pharmaceuticals and biotechnology. Its main offerings are cell therapy manufacturing, preclinical and clinical services and cell therapy technology development.
When was Cellares founded, and where is it based?
Cellares was founded in 2019 and is based in South San Francisco, United States. It has about 327 employees, up 18% over the last year.